Хърватия - хърватски - HALMED (Agencija za lijekove i medicinske proizvode)

the mentholatum company limited, 1 redwood avenue, peel park campus, east kilbride, ujedinjeno kraljevstvo - methylis nicotinas, salicylas hydroxyethylis, methylis salicylas, ethylis salicylas - sprej za kožu, otopina - 1,6 %, 5,0 %, 1,0 % i 5,0 % (m/m) - urbroj: 100 g sprej otopine sadržava: metilnikotinat 1,6%, hidroksietilsalicilat 5,0%, metilsalicilat 1,0%, etilsalicilat 5,0%

Хърватия - хърватски - HALMED (Agencija za lijekove i medicinske proizvode)

optinova d.o.o., zagreb - kapi za podmazivanje i vlaženje mekih kontaktnih leća

Хърватия - хърватски - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

biowet puławy sp. z.o.o., ul. arciucha 2, 24-100 puławy, poljska - oksitocin - otopina za injekciju - sustavni hormonski pripravci osim spolnih hormona i inzulina - goveda (krava), konja (kobila), svinja (krmača), ovaca, pasa (kuja), mačaka

Хърватия - хърватски - HALMED (Agencija za lijekove i medicinske proizvode)

sonimed d.o.o. rozganska 8 10110 zagreb -

Хърватия - хърватски - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

biowet puławy sp. z o.o., ul. arciucha 2, 24 -100 puławy, poljska - oksitocin - otopina za injekciju - goveda (krava), konja (kobila), svinja (krmača), ovaca, pasa (kuja), mačaka

Европейски съюз - хърватски - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenti za dermatitis, isključujući kortikosteroide - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Европейски съюз - хърватски - EMA (European Medicines Agency)

novartis europharm limited - trametinib - melanoma - antineoplastična sredstva - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 i 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. Немелкоклеточный rak pluća (НМРЛ)trametinib u kombinaciji s dabrafenib indiciran za liječenje odraslih bolesnika s preliminarnim non-mali raka pluća stanice s Браф mutacija v600 daleko .

Хърватия - хърватски - HALMED (Agencija za lijekove i medicinske proizvode)

tipex d.o.o., zagreb - mrežica za herniju

Хърватия - хърватски - HALMED (Agencija za lijekove i medicinske proizvode)

jasika d.o.o. za trgovinu i zastupanje remetinačka cesta 115 10000 zagreb -

Хърватия - хърватски - HALMED (Agencija za lijekove i medicinske proizvode)

mediva d.o.o. savska cesta 141 10000 zagreb -